Mission & Vision
Eclipse Life Sciences is developing therapeutic compounds to treat ophthalmological disease. These versatile compounds can treat both front-of-the-eye diseases, such as uveitis and dry eye as well as back-of-the-eye diseases such as wet or dry macular degeneration or diabetic retinopathy. Eclipse is planning to advance candidate drugs to treat both types of diseases.
Key Attributes
Core Expertise
Eclipse leadership has broad domain expertise across the full spectrum of ophthalmic research and development, from discovery and preclinical validation through nonclinical regulatory and clinical trials.
Five Attractive Drug Assets
The Eclipse pipeline is comprised of a novel topical eye drop for front-of-the-eye disease as well as four back-of-the-eye drugs, including both novel medicines and repositioned (505(b)2 and biosimilar) drugs, for various retinal diseases.
Patented Drug Delivery System
Eclipse back-of-the-eye drugs are enabled by a novel intravitreal multiphasic colloidal suspension-drug delivery system, a versatile biodegradable technology that is compatible with a variety of different molecule drug types and permits sustained release for 3-9 months.
Leadership Team
Scott Cousins, MD
CEO and VP of R&D
Dr. Cousins is CEO and VP of R&D and has led Eclipse Life Sciences since 2019. Prior to that, he was an internationally renowned clinician-scientist at Duke University, where he was head of the medical retina service, clinical trialist, and award-winning basic scientist. Prior to Eclipse, Dr. Cousins founded and led several other ophthalmology biotech startups. In addition, Dr. Cousins maintained over 3 dozen active collaborations with pharmaceutical companies, biotech startups, and investors, advising on preclinical development, clinical trial design, and marketing strategies.
Prithu Mettu, MD
Chief Medical Officer
Dr. Mettu serves as Chief Medical Officer for Eclipse. In this role, he oversees the design and conduct of Eclipse’s clinical research program. Dr. Mettu is an active medical retina specialist and clinician-scientist faculty member at Duke University. Previously, Dr. Mettu oversaw day-to-day operations of the Duke Ophthalmology Clinical Research Unit, where he oversaw over 140 open IRB clinical research protocols in the Department.
Mike Allingham, MD, PhD
Director, Preclinical Models
Dr. Allingham serves as Director, Preclinical Models. In this role, he oversees the non-GLP evaluation of tolerability and efficacy of Eclipse’s new drug assets. Dr. Allingham is an active medical retina specialist and clinician-scientist at Duke University, where he maintains an active research program and has an ongoing interest in animal models relating to retinal vascular diseases.
Eclipse Projects Pipeline
Eclipse is developing an innovative, diverse portfolio of first-in-class and best-in-class drugs in development for both “back-of-the-eye” and “front-of-the-eye” diseases, from discovery through Phase 2 proof-of-concept clinical trial. Drugs for back-of-the-eye retinal diseases are enabled by a novel, proprietary intravitreal extended-release drug delivery system.
Pipeline
IVT Fluocinolone XR
6 Month Corticosteroid for Diabetic Macular Edema (DME)
Nonclinical Regulatory IND-Enabling Studies
Topical CaM-I
Novel Eyedrop for Dry Eye Disease
Nonclinical Regulatory IND-Enabling Studies
IVT Mito XR
Novel Mitochondria-Targeted Prodrug for Dry Age-Related Macular Degeneration (AMD)
Nonclinical Regulatory IND-Enabling Studies
IVT CaM-I
Novel Anti-Inflammatory Prodrug for Wet AMD and DME
Nonclinical Regulatory IND-Enabling Studies
IVT Anti-VEGF XR
Sustained-Release Ranibizumab Biosimilar for Wet AMD, DME, and Retinal Vein Occlusion (RVO)
Nonclinical Regulatory IND-Enabling Studies